Navigation Links
FDA Gives 510k Clearance to EyeKor’s EXCELSIOR™ Cloud-based Image Management Software for Ophthalmic Clinical Trials
Date:5/3/2013

DAVIS, CA and MADISON, WI (PRWEB) May 03, 2013

EyeKor, LLC, a new service provider dedicated to the support of ocular clinical trials, announces FDA 510k clearance of its EXCELSIOR™ image management software as a class 2 medical device, with indications for use specifically for managing ophthalmic clinical trial data. A first-of-its kind web application, EXCELSIOR™ employs a unique cloud-based architecture to enhance efficiency and accuracy in the collection and interpretation of data from ophthalmic clinical trials. EXCELSIOR™ provides a framework in which images from multiple imaging modalities can be reviewed and analyzed concurrently.

According to EyeKor CEO Christopher J. Murphy, DVM, PhD, “EXCELSIOR™ is unique: No other software leverages data from such a wide variety of ophthalmic instruments while providing such a transparent workflow and ease of access.”

Murphy continues: “EyeKor’s unique relationships with nationally recognized reading centers position it to support EXCELSIOR™ by harnessing the expertise of multiple reading centers with a broad range of functionalities.” These include fundus imaging, corneal imaging, visual field assessment, and electrophysiology—all of which can be viewed and assessed from within the unified EXCELSIOR™ platform.

EXCELSIOR™ provides investigators, clinical trial sponsors, and data managers secure, real-time access to their data and lets them follow its progress through each workflow stage—collection, quality analysis, grading, and interpretation—through a browser interface. The platform is supported by Reading Center trained staff and technicians, who provide certification, clinical site support, and quality analysis of the images—with all analysis and grading harmonized by the EXCELSIOR™ custom viewer that features image-enhancement tools specifically configured for ease of use.

From acquisition to final analysis, EXCELSIOR™ is uniquely designed to meet the demands of ophthalmic clinical trials. EXCELSIOR™ leverages its web-based architecture, an intuitive workflow with a custom toolset, and a network of highly skilled clinical experts to provide faster, more accurate results across multiple test modalities in an accessible and transparent way. Murphy states: “This is the most streamlined and comprehensive software available to help ensure the successful analysis of ophthalmic clinical trial data.”

About EyeKor, LLC.
EyeKor, LLC., provides access to a coordinated network of established reading centers and clinical trial experts that offers a complete spectrum of integrated ophthalmic clinical trial services. The EXCELSIOR™ software platform is used to harmonize processes between diverse reading centers. EyeKor experts are unified through common standard operating procedures (SOPs), quality control and assurance, regulatory compliance, and computing infrastructure. The company’s expertise encompasses a diverse array of ophthalmic testing methods that include fundus photograph and angiography, optical coherence tomography, fundus autofluorescence imaging, automated visual field testing, specular microscopy imaging and electrophysiological testing.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10686249.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. U.S. Gives Green Light to Publish Controversial Bird Flu Research
2. Image share project gives patients and physicians anytime, anywhere access to medical images
3. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
4. UMD team gives drug dropouts a second chance
5. FDA Panel Gives Blessing to New Weight-Loss Drug
6. Amazon Tribe Gives Clues to Heart-Healthy Lifestyles
7. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
8. Aurora Dentist Gives Patients Big Savings With Teeth in a Day Implants
9. OC Firm Gives Back to Young Athletes
10. Study Gives First Evidence That Adult Human Lungs Can Regrow
11. FDA Gives Nod to New Breast Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... FALLS CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... , worries, or problems. He has also continued to spiritually evolve, which is the ... his published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as well ... solution helps transform the HCC Risk Adjustment process from a typical fragmented ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier ... absorption from the mouth into the bloodstream. Far outpacing the absorption ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, ... is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... of neurosurgeons in Michigan performing minimally invasive back surgery that often results in ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... Mass. , Feb. 23, 2017   ... partner to global in vitro diagnostics manufacturers and ... series titled "Catalyzing Implementation of NGS-Based Tests" to ... March 30, 2017 at 11am Eastern Standard Time ... is to highlight the need for improved performance ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology: